Plain-English translation of NCT04055649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called ONC201 paired with a chemotherapy drug called in women whose ovarian, fallopian tube, or peritoneal cancer has returned or stopped responding to standard platinum-based chemotherapy. ONC201 works by targeting specific cancer cell pathways, and researchers believe combining it with may help control this hard-to-treat cancer. The study will measure how well this treatment works, how safe it is, and how long people survive.
When ovarian cancer stops responding to standard platinum-based chemotherapy, options become very limited and outcomes are often poor. This medication is being tested because laboratory and early clinical studies suggest it may work differently than current treatments and could help patients whose cancer has become resistant to standard therapy.
You likely qualify if…
You likely don't qualify if…
You would take ONC201 by mouth on days 1, 8, 15, and 22 of each 28-day cycle, and receive as an intravenous infusion on days 2, 9, and 16. The treatment cycles repeat as long as your cancer does not progress and you are tolerating the medication well. If needs to be stopped for any reason, you may continue taking ONC201 alone. You will have regular clinic visits and blood tests to monitor how you are responding and to check for side effects.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States